The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was valued at USD 3.8 Billion in 2021 and is expected to reach USD 5.5 Billion by 2030, finds Future Market Insights (FMI) in a recent market survey.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 3.9 Billion |
| Market Value 2030 | USD 5.5 Billion |
| CAGR 2022 to 2030 | 4.3% |
| Key Players | The key players are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herbal Intervention, LLC, 3M ESPE Dental Products, Patterson Dental Supply Inc., The Kroger Company, Crown Laboratories, Inc., Atlantic Biologicals Corp., Bio-Germ Protection LLC and Apollo Health and Beauty Care |
| Share of Top 5 Countries | 65.9% |
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is anticipated to witness robust growth due to the growing incidence rate of MRSA infections, increasing number of pipeline products, and growing product approval & launches for the MRSA infection treatment.
One of the significant type of MRSA infection is surgical infections. This risk of infections is associated with several surgical conditions which demand surgical procedures. Rising number of surgical conditions from chronic diseases such as diabetes, chronic respiratory and renal diseases are expected to increase the demand of post-operative MRSA anti-infective therapies.
Methicillin-resistant staphylococcus aureus (MRSA) treatment market holds nearly 18.1% market value share of the USD 21 Billion skin disease treatment market in 2021. In addition, leading industry players are focusing on development and launch of next generation antibiotics to treat MRSA infections. This accelerated availability of antibiotics in the market is expected to boost the MRSA treatment market.
Driven by this, sales of methicillin-resistant staphylococcus aureus (MRSA) treatment are expected to rise at a 4.3% CAGR through 2030.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.25% |
| H1, 2022 Projected | 4.34% |
| H1, 2022 Outlook | 4.24% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 1 ↓ |
FMI presents a comparative analysis about the market growth rates and development prospects in the global methicillin resistant Staphylococcus aureus (MRSA) treatment market. In response to the impact of macro and industrial factors, the market is influenced by an increase in patient base and economic disparities in regional medical setups. Source control and the initiation of active antimicrobial therapy are two major advancements in this sector.
The market for methicillin-resistant Staphylococcus aureus (MRSA) therapy is expected to fall by just 01 Basis Point Share (BPS) in H1-2022, according to FMI. The disruption created by the COVID-19 pandemic, as well as the lack of clear protocols for MRSA treatment in numerous countries, are key factors in the decline of BPS. Moreover, a decline of 10 BPS will be observed in the market within the periods of H1-2022 outlook over H1-2022 projected.
On the other hand, there are certain advantages for the industry, such as combination therapy with Vancomycin and Daptomycin. Physicians employ heterogeneous practice patterns with vancomycin or daptomycin monotherapy for MRSA, with combination antibiotic therapy reserved for patients at higher risk of treatment failure.
Sales of methicillin-resistant staphylococcus aureus (MRSA) treatment grew at a CAGR of 4.1% between 2015 and 2021.
The primary factors contributing to the development of the methicillin-resistant staphylococcus aureus (MRSA) treatment market are increase in the worldwide occurrence of MRSA infections, a rise in public and private funding for R&D of new anti-MRSA drugs and their enhanced screening.
For instance, as per the CDC, around 2% of the overall population carries MRSA. Moreover, the growing practice of prescribing inappropriate and unnecessary antibiotics leading to the increase in MRSA infections is expected to boost the growth of the global market.
In addition, companies are focusing on product releases and research for the detection of MRSA, which is boosting the global MRSA treatment market.
For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the USA market.
Considering this, FMI expects the global methicillin-resistant staphylococcus aureus (MRSA) treatment market to grow at a CAGR of 4.3% through 2030.
Principal Consultant
Poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MSRA treatment market.
S. aureus and MRSA produce considerable economic challenges for healthcare professionals owing to the effect they have on quality of care, patient safety, and overall healthcare expenses. High cost related with MRSA infections treatment is anticipated to hinder the treatment adoption rate specifically in emerging regions.
In addition, incorrect diagnoses of MRSA may result into inappropriate delivery and management of patient care, which, in turn, results into severe primary and secondary complications, including death. All such factors may hinder the market growth in the near future.
The USA is estimated to account for around 93.2% of the North America methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
USA is anticipated to lead the global MRSA treatment market over the forecast period. This market share is majorly owing to the funding by USA based companies in the research and development of assessment tools for MRSA infection. In addition, the increase in government support for treatment of MRSA lung infection in patients with cystic fibrosis has boosted the market.
For instance, Cystic Fibrosis Foundation, in 2018, at North American Cystic Fibrosis Conference declared that it will spend a minimum of USD 100 million for the next five years to support enhanced diagnosis, detection, prevention, and treatment of infections associated to cystic fibrosis.
UK. is estimated to account for 14.7% of the Europe methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
UK. is the one of the prominent country in the European market owing to research grants by the private & public companies in the European countries to boost the research and development of anti-MRSA antibiotics.
In addition, the government of the UK is undertaking serious steps to avoid the incidence of SSI (surgical site infections) in the nation. Thus, the increasing efforts and preventive measures undertaken by the government for surgical site infections control are leading to the growth of the market in UK.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market in China is estimated to be worth USD 156.6 Million in 2022 in the global market.
China is expected to observe considerable growth during the forecast period owing to a huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao
Demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in India is expected to rise at around 5.4% CAGR over the forecast period.
India is expected to witness considerable growth owing to larger patient population and the uncontrolled utilization of antibiotics in India. Resistance to antibiotics is continuously growing due to incomplete prescribed course of antibiotics that allows some bacteria to persist, grow a resistance to the antibiotic.
Moreover, misuse of antibiotics in non-regulated and developing nations is also anticipated to drive the cases of MRSA infections in the coming years. This is leading to increasing demand for the MRSA infection treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By drug class, glycopeptides is anticipated to hold the maximum share of 61.2% in 2022, expanding at rate of nearly 4.1% during the forecast period, due to growing focus of market players on manufacturing of advanced drugs in this class. Vancomycin and teicoplanin are some of the present glycopeptide drugs in the market.
Moreover, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
By indication, skin and soft tissue infections (SSTIs) will lead the market and is projected to account for 40.9% of the total market revenue share in 2022.
The growing incidence of MRSA (methicillin-resistant staphylococcus aureus) infections has led to the need for novel therapies to fight the serious skin and soft tissue infections. Moreover, new product launches will drive the growth of the skin and soft tissue infections (SSTIs) segment over the forecast period.
In terms of route of administration, intravenous segment in projected to account for 57.2% of the total market share in 2022.
The intravenous route of administration is the most preferred route as it is the first line of therapy and the fastest route of drug delivery. This delivers the drug rapidly and gives the patient rapid relieve from the disease. This enhances the drug action and gives the patient first line of treatment.
By types of MRSA, healthcare acquired MRSA will lead the market and is projected to account for 51.2% of the total market revenue share in 2022.
Hospital-acquired MRSA hospitalizations are those with a secondary or principal MRSA detection that is not present on admission; this indicates that the MRSA condition occurred during the hospitalization. The hospital acquired MSRA cases is increasing due to the rising number of surgical procedures and unhygienic conditions.
By distribution channel, hospital pharmacies segment is anticipated to hold the maximum share of 62.6% in 2022, expanding at rapid rate of 3.9% CAGR during the forecast period.
The number of hospitals are growing, particularly in the developed nations, which is anticipated to surge the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in hospitals. Moreover, presence of well-developed infrastructure and availability of advanced equipment supports the development of the segment.
Also, the increasing patient admission in hospitals is increasing the use of these drugs in hospitals, thus driving the sales in hospital pharmacies.
Companies operating in the Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market are moderately competitive by nature, with a presence of several players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
| Attribute | Details |
|---|---|
| Forecast Period | 2015 to 2021 |
| Historical Data Available for | 2022 to 2030 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
| Key Segments Covered | Drug Class, Indication, Route of Administration, Types of MSRA, Distribution Channel and Region |
| Key Companies Profiled | Pfizer, Inc.; Allergan Plc.; Johnsons & Johnson; Colgate-Palmolive Company; The Procter & Gamble; Merck & Co., Inc.; Baxter Healthcare Corporation; Fresenius Kabi LLC; Sandoz Inc.; Teva Pharmaceutical Industries ltd.; Mylan N. V.; Dr.Reddy's Laboratories Inc.; Cumberland Pharmaceuticals Inc.; Durata Therapeutics Inc.; Melinta Therapeutics, Inc.; Debiopharm International S.A.; Cardinal Health; Amazon Inc.; Herbal Intervention, LLC; 3M ESPE Dental Products; Patterson Dental Supply Inc.; The Kroger Company; Crown Laboratories, Inc.; Atlantic Biologicals Corp.; Bio-Germ Protection LLC; Apollo Health and Beauty Care |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global methicillin-resistant staphylococcus aureus (MRSA) treatment market is worth USD 3.8 Billion in 2021 and is set to expand 1.4X over the forecast years.
The sales of methicillin-resistant staphylococcus aureus (MRSA) treatment in the market have grown at a CAGR of nearly 4.1% between 2015 and 2021.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to reach USD 5.5 Billion by the end of 2030 with sales revenue expected to register CAGR of 4.3% over the forecast period.
North America currently holds the largest market share in the methicillin-resistant staphylococcus aureus (MRSA) treatment with an estimation of nearly 48.5% in 2022 of the global market share. USA continues to be the leading contributor with a market value over USD 1.7 Billion in 2022.
Demand of methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to register growth in Europe at rate of 4.4% CAGR during the forecast period.
The methicillin-resistant staphylococcus aureus (MRSA) treatment in China is likely to observe growth with an impressive CAGR of 5.1% during the forecast period. The key factors fueling the development of the market include huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
Development of alternative oral & topical dosage forms, extension of antibiotic class to newer therapeutics, rise of specialized companies in antibiotics developments and commercialization and national healthcare authority’s active engagement to combat MRSA are key trends driving sales of methicillin-resistant staphylococcus aureus (MRSA) treatment market across the globe.
Japan’s methicillin-resistant staphylococcus aureus (MRSA) treatment market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 5.6% CAGR during the forecast period. South Korea market expected to exhibit healthy growth of 7.0% CAGR during the forecast period.
USA, Germany, France, UK and Italy are the top 5 countries driving the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment market.
Leading companies of methicillin-resistant staphylococcus aureus (MRSA) treatment are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herb
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Market Background 5. Market Context 6. Global Market Value (USD Million) Analysis 2015 to 2021 and Forecast, 2022 to 2030 7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Drug Class 7.1. Glycopeptides 7.1.1. Vancomycin 7.2. Lipopeptides 7.2.1. Daptomycin 7.3. Oxazolidinones 7.3.1. Linezolid 7.4. Glycylcycline 7.4.1. Tigecycline 7.5. Streptogramins 7.5.1. Quinupristin 7.5.2. Dalfopristin 7.6. Lincomycin 7.6.1. Clindamycin 7.7. Tetracycline 7.7.1. Doxycycline 7.7.2. Minocycline 7.8. Lipoglycopeptides 7.8.1. Dalbavancin 7.8.2. Telavancin 7.8.3. Oritavancin 7.9. Antiseptics 7.9.1. Chlorhexidine 7.9.2. Cetylpyridinium Chloride 7.9.3. Hydrogen Peroxide 7.9.4. Phenols 7.10. Naturals/Herbals 7.11. Others 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Indication 8.1. Skin and Soft Tissue Infections (SSTIs) 8.2. Pneumonia 8.3. Bloodstream Infections 8.4. Surgical and Medical Infections 8.5. Others 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Route of Administration 9.1. Intravenous 9.2. Oral 9.3. Topical 9.4. Nasal 9.5. Cutaneous 9.6. Intramuscular 10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Types of MRSA 10.1. Healthcare Acquired MRSA 10.2. Community Acquired MRSA 10.3. Hospital Acquired MRSA 11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, By Distribution Channels 11.1. Hospital Pharmacies 11.2. Retail Pharmacies 11.3. Drug Stores 11.4. Online Pharmacies 12. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2030, by Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia Pacific 12.6. Middle East and Africa (MEA) 13. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2030 14. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2030 15. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2030 16. South Asia and Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2030 17. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2030 18. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2030 19. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2030 20. Emerging Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2030 21. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2030 22. Market Structure Analysis 23. Competition Analysis 23.1. Pfizer, Inc. 23.2. Allergan Plc. 23.3. Johnson & Johnson 23.4. Colgate-Palmolive Company 23.5. The Procter & Gamble 23.6. Merck & Co., Inc. 23.7. Baxter Healthcare Corporation 23.8. Fresenius Kabi LLC 23.9. Sandoz Inc. 23.10. Teva Pharmaceutical Industries Ltd. 23.11. Mylan N.V. 23.12. Dr. Reddy's Laboratories Inc. 23.13. Cumberland Pharmaceuticals Inc. 23.14. Durata Therapeutics Inc. 23.15. Melinta Therapeutics, Inc. 23.16. Debiopharm International S.A. 23.17. Cardinal Health 23.18. Amazon Inc. 23.19. Herbal Intervention, LLC 23.20. 3M ESPE Dental Products 23.21. Patterson Dental Supply Inc. 23.22. The Kroger Company 23.23. Crown Laboratories, Inc. 23.24. Atlantic Biologicals Corp. 23.25. Bio-Germ Protection LLC 23.26. Apollo Health and Beauty Care 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market
